| ISSN |
2220-3230 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Transplantation |
| Manuscript Type |
Retrospective Study |
| Article Title |
Impact of cytochrome P450 3A5 expression on clinical outcomes in renal transplant recipients receiving tacrolimus-based immunosuppression
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Amit S Pasari, Sunny Malde, Priyanka Tolani, Vishal Ramteke, Sushrut Gupta, Twinkle Pawar, Vijay Jeyachandran, Kapil Sejpal, Mohit Kurundwadkar, Prasad Gurjar, Pranjal Kashiv, Shubham Dubey, Charulata Bawankule, Vivek B Kute, Nishant Deshpande and Manish Ramesh Balwani |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Vishal Ramteke, MD, Department of Nephrology, Max Super Speciality Hospital, 232 Mankapur Koradi Road, Nagpur 440030, Mahārāshtra, India. vvramteke@gmail.com |
| Key Words |
Cytochrome P450 3A5 expression; Polymorphism; Renal transplant; Tacrolimus; Tacrolimus trough concentration (ng/mL)/daily tacrolimus dose (mg/kg/day) ratio |
| Core Tip |
This study evaluated the effect of cytochrome P450 3A (CYP3A) 5 polymorphism on tacrolimus pharmacokinetics and clinical outcomes in renal transplant recipients. CYP3A5 expressors required significantly higher tacrolimus doses than non-expressors from 6 months onward to maintain therapeutic levels. Non-expressors consistently showed higher tacrolimus trough concentration (ng/mL)/daily tacrolimus dose (mg/kg/day) ratios, reflecting slower drug metabolism. Despite these differences, no significant impact was seen on acute rejection rates, renal function, or complications such as new onset diabetes after transplantation and hypomagnesemia. These findings emphasize the importance of genotype-guided tacrolimus dosing for individualized immunosuppressive management, while therapeutic drug monitoring helps mitigate clinical variability, ensuring comparable outcomes between expressors and non-expressors. |
| Publish Date |
2025-11-19 05:57 |
| Citation |
<p>Pasari AS, Malde S, Tolani P, Ramteke V, Gupta S, Pawar T, Jeyachandran V, Sejpal K, Kurundwadkar M, Gurjar P, Kashiv P, Dubey S, Bawankule C, Kute VB, Deshpande N, Balwani MR. Impact of cytochrome P450 3A5 expression on clinical outcomes in renal transplant recipients receiving tacrolimus-based immunosuppression. <i>World J Transplant</i> 2025; 15(4): 107636</p> |
| URL |
https://www.wjgnet.com/2220-3230/full/v15/i4/107636.htm |
| DOI |
https://dx.doi.org/10.5500/wjt.v15.i4.107636 |
